Neurocrine Biosciences (NBIX) FY2015 results: revenue $20 million
Neurocrine Biosciences Inc. (NBIX) reported revenue of $20 million for fiscal 2015, the year ended 31 December 2015. Net income was -$89 million, and diluted earnings per share $-1.05. The figures are the company's own, from the 10-K it filed with the SEC on 11 February 2016.
Revenue
$20 million
FY2009FY2015
Operating margin
-476.5%
FY2009FY2015
Net income
-$89 million
FY2009FY2015
Diluted EPS
-$1.05
FY2009FY2015
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Revenue
19.8
0.0
2.9
Cost of revenue
0.0
n/a
n/a
Gross profit
19.8
n/a
n/a
Gross margin
100.0%
n/a
n/a
Research and development
81.5
46.4
39.2
+75.5%
Selling, general and administrative
32.5
n/a
n/a
Operating income
-94.2
-64.4
-49.7
Operating margin
-476.5%
n/a
-1701.9%
Interest expense
0.0
n/a
n/a
Income tax
0.0
0.0
0.0
Net income
-88.9
-60.5
-46.1
Net margin
-449.8%
n/a
-1579.0%
Diluted EPS
-$1.05
-$0.81
-$0.69
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Operating cash flow
-38.0
-47.1
-29.6
Capital expenditure
1.9
1.6
0.5
+20.0%
Free cash flow
-39.9
-48.8
-30.2
Free cash flow margin
-202.0%
n/a
-1033.0%
Cash from investing
n/a
n/a
5.3
Cash from financing
n/a
n/a
5.3
Depreciation and amortisation
1.0
0.8
0.7
+22.0%
Share-based compensation
28.4
10.4
6.8
+173.5%
Diluted shares, weighted
84m
75m
67m
+13.3%
Shares outstanding at period end
86m
76m
67m
+12.8%
Balance sheet
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Shareholders' equity
424
209
120
+103.4%
Debt
0.0
0.0
0.0
Other liabilities
50.3
34.3
34.3
+46.6%
Total liabilities and equity
475
243
155
+95.4%
Fixed assets
3.4
2.5
1.8
+36.9%
Investments
387
200
101
+93.5%
Cash and equivalents
74.2
31.0
44.8
+139.2%
Receivables
n/a
n/a
0.0
Other assets
9.7
9.2
7.1
+4.9%
Total assets
475
243
155
+95.4%
10-K for the year ended 31 December 2015, filed 11 February 2016: the filing.